Trajenta Duo 2.5mg/1000mg Tablet

Trajenta Duo 2.5mg/1000mg Tablet is a combination of two medicines that control high blood sugar levels in people with type 2 diabetes mellitus. This helps prevent serious complications of diabetes such as kidney damage and blindness and may reduce your chance of having a heart attack or stroke.

Trajenta Duo 2.5mg/1000mg Tablet can be prescribed alone or together with other diabetes medications. All diabetes medicines work best when used along with a healthy diet and regular exercise. The dose you are given will depend on your condition, blood sugar levels, and what other medicines you are taking. Taking this medicine with meals helps to reduce the chances of developing an upset stomach.

You should take it regularly, at the same time each day, to get the most benefit. You should not stop this medicine unless your doctor recommends it. It is controlling your blood sugar levels and helping to prevent serious complications in the future. Your lifestyle plays a big part in controlling diabetes. Therefore, it is important to stay on the diet and exercise program recommended by your doctor while taking this medicine.

The most common side effects of taking this medicine include diarrhea, nausea, vomiting, upset stomach, headache, blocked nose (nasal congestion), and sore throat. Low blood sugar level (hypoglycemia) is a possible side effect if you are also taking other diabetes medicines like insulin, glimepiride, or sulphonylurea. So you need to know how to recognize and deal with it.

This medicine is not suitable for everyone. Before taking it, you should let your doctor know if you have ever had kidney, liver, or heart disease, problems with your pancreas, or if you drink a lot of alcohol. Pregnant or breastfeeding women should also consult their doctor before taking this medicine. Some other medicines may affect the working of this medicine, so tell your doctor about all the medicines you are taking to make sure you are safe. You should try to avoid drinking alcohol as it lowers blood sugar. Your doctor will check your kidney function and blood sugar levels before and during treatment.

• Treatment of Type 2 diabetes mellitus

Treatment of Type 2 diabetes mellitus
Trajenta Duo 2.5mg/1000mg Tablet has two active substances in it i.e. metformin and linagliptin. Metformin belongs to a class of medicines called biguanides. Linagliptin belongs to a group called DPP-4 inhibitors. They work together in different ways to lower your blood glucose levels.

Lowering blood glucose levels is an essential part of managing diabetes. If you can control your blood glucose level, your risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems, and loss of limbs is also lowered. Additionally, proper control of diabetes can also reduce the risk of heart disease and stroke. Taking this medicine regularly along with a proper program of diet and exercise will help you live a normal, healthy life. You should keep using this medicine for as long as it is prescribed because it is protecting your future health.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Ondero Met

• Hypoglycemia (low blood glucose level)
• Nausea
• Diarrhea
• Vomiting
• Flatulence
• Weight gain

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Trajenta Duo 2.5mg/1000mg Tablet is to be taken with food.

Trajenta Duo 2.5mg/1000mg Tablet is a combination of two antidiabetic medicines: Metformin and Linagliptin. Metformin is an antidiabetic medication (biguanide). It works by lowering the glucose production in the liver, delaying glucose absorption from the intestines and increasing the body's sensitivity to insulin. Linagliptin is a DPP-4 inhibitor which works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces both fasting and postmeal sugar levels. Together, they provide better control of blood sugar.

• You have been prescribed this combination medicine as it can control blood sugar better than metformin alone.
• Trajenta Duo 2.5mg/1000mg Tablet should be taken with food to lower the chances of having an upset stomach.
• Take it in addition to regular exercise and a healthy diet to lower the levels of blood sugar.
• Chances of weight gain and low blood sugar are lesser as compared to other diabetes medicines.
• Hypoglycemia (low blood sugar level) may occur when taken along with other antidiabetic medicines, alcohol or on delaying/skipping a meal. Carry a sugar source with you for immediate relief.
• Monitor your blood sugar level regularly while you are taking this medicine.
• Inform your doctor about your diabetes treatment if you are due to have any surgery under a general anesthetic.
• Tell your doctor immediately if you experience any deep or rapid breathing, persistent nausea, vomiting, or stomach pain as Trajenta Duo 2.5mg/1000mg Tablet may cause a rare but serious condition called lactic acidosis, which is an excess of lactic acid in the blood.

Linagliptin/metformin hydrochloride. Koropi, Greece: Boehringer Ingelheim Ellas A.E.; 2018. [Accessed 28 Jan. 2019] (online) Available from:

Linagliptin and metformin hydrochloride. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012. [Accessed 28 Jan. 2019] (online) Available from:

Metformin hydrochloride. Princeton, New Jersey: Bristol-Myers Squibb Company. [Accessed 08 Apr. 2019] (online) Available from:

Linagliptin. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc.; 2014. (online) [Accessed 08 Apr. 2019] Available from:

Linagliptin/Metformin hydrochloride tablets [Product monograph]. Ontario, Canada: Boehringer Ingelheim (Canada) Ltd.; 2021. [Accessed 20 Oct. 2021] (online) Available from:

Linagliptin/Metformin hydrochloride tablets [Product monograph]. Ontario, Canada: Boehringer Ingelheim (Canada) Ltd.; 2019. [Accessed 20 Oct. 2021]. (online) Available from: